期刊
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
卷 63, 期 6, 页码 949-972出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2010.02.062
关键词
atopic dermatitis; calcineurin inhibitors; cyclosporine; diug interactions; pharmacokinetics; psoriasis
类别
资金
- Elsevier
- 3M/Graceway Pharmaceuticals
- Genentech
- Astellas Pharmaceuticals
- Abbott
- Astellas
- Centocor
- Eli Lilly
- Novartis
- Novo Nordisk
- Pfizer
- Promius
- Syntrix
- Warner Chilcott
Cyclosporine is highly effective in the treatment of a multitude of dermatoses. Concern over its side effect profile has limited its use in dermatology. Adverse effects are, for the most part, dose dependent and related to duration of therapy. Using the recommended monitoring protocols results in a significant decrease in the incidence of cyclosporine-related toxicities. This article provides a comprehensive review of the pharmacokinetics of cyclosporine, potential drug interactions, adverse effects, and recommendations for monitoring in patients treated with cyclosporine. The use of cyclosporine in pregnancy and in the pediatric population is also addressed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据